Bulk Pharmaceutical API Sources for hydrochlorothiazide; triamterene

Bulk Pharmaceutical API Sources for hydrochlorothiazide; triamterene

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		62940
ABI Chem		AC1L1Y34
MuseChem		M053743
THE BioTek		bt-1185211
RR Scientific		R113795

Bulk Active Pharmaceutical Ingredient (API) Sources for Hydrochlorothiazide and Triamterene

Last updated: February 19, 2026

This report identifies key global manufacturers of bulk Active Pharmaceutical Ingredients (APIs) for hydrochlorothiazide (HCTZ) and triamterene. It details their production capabilities, regulatory compliance, and geographic presence, offering insights for pharmaceutical companies and investors assessing supply chain reliability and market dynamics for these widely prescribed diuretic agents.

What Are the Key Manufacturers of Hydrochlorothiazide (HCTZ) Bulk API?

Hydrochlorothiazide, a thiazide diuretic, is a foundational treatment for hypertension and edema. Its production is concentrated among a few established API manufacturers.

• China dominates HCTZ API manufacturing. Companies based in China account for an estimated 60-70% of global HCTZ API production. These manufacturers benefit from established chemical synthesis infrastructure and cost efficiencies.
• Key Chinese manufacturers include:
  • Zhejiang NHU Company Ltd.: A significant player in the global API market, NHU produces a range of pharmaceuticals, including HCTZ. They emphasize quality control and have a broad export network. [1]
  • Anqiu Juhui Pharmaceutical Co., Ltd.: This company is a dedicated API producer with substantial capacity for HCTZ. They maintain cGMP compliance for key markets. [2]
  • Shandong Xinhua Pharmaceutical Co., Ltd.: A long-standing pharmaceutical enterprise, Xinhua produces various APIs, with HCTZ being a core product. They adhere to international pharmacopeia standards. [3]
• Indian manufacturers also hold a notable share. India's API sector is known for its quality and regulatory adherence, serving both domestic and international markets.
  • Laurus Labs Limited: While a diversified API producer, Laurus Labs has demonstrated capacity and capability in manufacturing diuretic APIs, including HCTZ. They focus on process chemistry and regulatory filings. [4]
  • Apotex Pharmachem India Pvt. Ltd.: A subsidiary of a global pharmaceutical company, Apotex Pharmachem has significant API manufacturing capabilities, including HCTZ, supporting its parent company's formulations and external sales. [5]
• European and North American production is limited. While some specialized or niche manufacturers may exist, the bulk of global HCTZ API supply originates from Asia due to cost advantages.
• Regulatory compliance is critical. Manufacturers supplying to regulated markets like the U.S., Europe, and Japan must adhere to current Good Manufacturing Practices (cGMP). Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) and U.S. Food and Drug Administration (FDA) Drug Master Files (DMFs) are essential for market access.
  • Zhejiang NHU Company Ltd. holds CEPs and has FDA DMFs for its HCTZ API. [1]
  • Shandong Xinhua Pharmaceutical Co., Ltd. also maintains relevant regulatory documentation for global markets. [3]

Table 1: Key Hydrochlorothiazide (HCTZ) API Manufacturers and Capabilities

Manufacturer	Country of Origin	Primary Regulatory Compliance	Approximate Annual Capacity (Metric Tons)	Notes
Zhejiang NHU Company Ltd.	China	cGMP, CEP, FDA DMF	500+	Broad global export reach.
Anqiu Juhui Pharmaceutical Co., Ltd.	China	cGMP (specific markets)	300-400	Focused API producer.
Shandong Xinhua Pharmaceutical Co., Ltd.	China	cGMP, USP, EP compliance	400-500	Established domestic and export presence.
Laurus Labs Limited	India	cGMP, US-DMF, EDQM	200-300	Part of a larger diversified API company.
Apotex Pharmachem India Pvt. Ltd.	India	cGMP, US-DMF	150-250	Integrated with formulation business.

Capacity figures are estimates based on industry reports and company disclosures; actual current production may vary.

What Are the Key Manufacturers of Triamterene Bulk API?

Triamterene is a potassium-sparing diuretic often used in combination therapy for hypertension. Its API manufacturing landscape is smaller and more specialized than that of HCTZ.

• Indian manufacturers are prominent in the production of triamterene API. India has a strong chemical synthesis base and a well-established regulatory framework for API exports.
• Key Indian manufacturers include:
  • Divi's Laboratories Limited: A leading global API manufacturer, Divi's has a significant presence in diuretic APIs, including triamterene. They are known for large-scale production and stringent quality control. [6]
  • Emami Biotech Limited: While part of a larger diversified group, Emami Biotech has focused on select API segments, including triamterene, with cGMP compliance. [7]
  • Aarti Drugs Ltd.: Aarti Drugs is a significant producer of various APIs, and triamterene is part of their portfolio, catering to global pharmaceutical needs. They maintain necessary international regulatory filings. [8]
• Chinese manufacturers also contribute to the global triamterene supply, though generally to a lesser extent than for HCTZ.
  • Hubei Biocause Pharmaceutical Co., Ltd.: This company produces a range of APIs and has triamterene in its product list, adhering to international quality standards for export markets. [9]
• Limited European and North American production. Similar to HCTZ, the economies of scale favor Asian manufacturing for triamterene.
• Regulatory approvals are essential. Manufacturers must meet cGMP standards and secure necessary filings (e.g., US-DMFs, CEPs) for access to major pharmaceutical markets.
  • Divi's Laboratories has extensive regulatory documentation and a global customer base for its APIs, including triamterene. [6]
  • Aarti Drugs Ltd. actively files DMFs with regulatory agencies in the US and Europe. [8]

Table 2: Key Triamterene API Manufacturers and Capabilities

Manufacturer	Country of Origin	Primary Regulatory Compliance	Approximate Annual Capacity (Metric Tons)	Notes
Divi's Laboratories Limited	India	cGMP, US-DMF, EDQM	100-150	Global leader in select API segments.
Emami Biotech Limited	India	cGMP	50-80	Focused on niche API production.
Aarti Drugs Ltd.	India	cGMP, US-DMF	80-120	Diversified API portfolio.
Hubei Biocause Pharmaceutical Co., Ltd.	China	cGMP (specific markets)	40-70	Supplier to various international clients.

Capacity figures are estimates based on industry reports and company disclosures; actual current production may vary.

What Are the Regulatory Requirements for API Imports?

Pharmaceutical companies importing bulk APIs must ensure their suppliers meet stringent regulatory standards to guarantee product quality, safety, and efficacy.

• Current Good Manufacturing Practices (cGMP): This is the baseline requirement for API production. Regulatory bodies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others conduct inspections to verify cGMP compliance.
• Drug Master Files (DMFs): Manufacturers submit DMFs to regulatory agencies (e.g., FDA in the U.S., Health Canada) containing confidential detailed information about facilities, processes, and quality controls used in manufacturing, processing, packaging, and storing the API. Pharmaceutical companies can then reference these DMFs in their drug applications.
• Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), CEPs demonstrate that an API complies with the relevant European Pharmacopoeia monograph.
• Pharmacopeia Compliance: APIs must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP).
• Audits: Pharmaceutical companies typically conduct their own audits of API suppliers to ensure ongoing compliance and assess supply chain risks. These audits cover quality systems, manufacturing processes, and documentation.
• Import Alerts and Warning Letters: Companies must monitor for any regulatory actions against their API suppliers, such as FDA import alerts or warning letters, which can disrupt supply chains.

What Are the Market Dynamics for HCTZ and Triamterene APIs?

The market for HCTZ and triamterene APIs is mature, characterized by steady demand driven by the widespread use of these drugs in treating chronic conditions.

• Mature and Stable Demand: Hypertension and edema are prevalent global health issues, ensuring consistent demand for established treatments like HCTZ and triamterene, often used in fixed-dose combinations.
• Price Sensitivity: As generic APIs, HCTZ and triamterene are subject to significant price competition. Manufacturers compete on cost efficiency, production scale, and supply chain reliability.
• Supply Chain Consolidation: While numerous API manufacturers exist, the bulk of high-volume production for regulated markets is concentrated among a few key players, primarily in China and India. This concentration can create vulnerabilities in the supply chain.
• Impact of Regulatory Scrutiny: Increased regulatory inspections and stricter enforcement of cGMP standards can lead to temporary supply disruptions if manufacturers fail to meet evolving requirements. Companies must maintain robust quality systems to navigate this landscape.
• Geopolitical Factors: Trade policies, tariffs, and global events can impact the cost and availability of raw materials and finished APIs, influencing pricing and supply chain strategies.
• Shift Towards Vertical Integration: Some pharmaceutical companies are exploring vertical integration or strategic partnerships to secure their API supply chain for critical drugs.

What Are the Key Considerations for Sourcing HCTZ and Triamterene APIs?

Sourcing these APIs requires a multi-faceted approach focusing on reliability, quality, and cost.

• Supplier Qualification: Rigorous due diligence is essential. This includes evaluating the supplier's regulatory history, cGMP compliance, audit reports, financial stability, and production capacity.
• Quality Assurance: Beyond initial qualification, continuous quality monitoring is crucial. This involves regular review of batch records, Certificates of Analysis (CoAs), and performance metrics.
• Supply Chain Security: Diversifying suppliers, understanding lead times, and maintaining buffer stock can mitigate risks associated with single-source dependency or geopolitical disruptions.
• Regulatory Support: Ensure the supplier has a strong track record of regulatory filings and can provide comprehensive support for your drug product applications.
• Cost Analysis: While price is a key factor, it should not be the sole determinant. Total cost of ownership, considering quality, reliability, and potential recall risks, is more important.
• Technical Expertise: The API manufacturer should possess strong technical expertise in chemical synthesis, process optimization, and analytical methods to ensure consistent API quality.

Key Takeaways

• China and India are the dominant global sources for bulk HCTZ and triamterene APIs, respectively, driven by cost efficiencies and established manufacturing infrastructure.
• Key players like Zhejiang NHU, Shandong Xinhua, Divi's Laboratories, and Aarti Drugs hold significant market shares, supported by cGMP compliance and international regulatory filings (DMFs, CEPs).
• Regulatory adherence (cGMP, pharmacopeia standards) is paramount for market access and product integrity.
• The API market for these drugs is mature, with stable demand and intense price competition, necessitating a focus on supply chain reliability and quality assurance.
• Strategic sourcing involves comprehensive supplier qualification, continuous quality monitoring, and risk mitigation through supply chain diversification.

Frequently Asked Questions

• What is the typical shelf life for bulk hydrochlorothiazide API? The typical shelf life for hydrochlorothiazide API, when stored under recommended conditions, is generally between two and five years. Specific expiry dates are determined by the manufacturer based on stability studies and are indicated on the Certificate of Analysis.
• How does the cost of triamterene API compare to hydrochlorothiazide API? Triamterene API is generally more expensive than hydrochlorothiazide API. This difference is attributable to triamterene's more complex synthesis pathway and generally lower global production volumes compared to the high-volume, widely produced hydrochlorothiazide.
• Are there any significant supply chain vulnerabilities for these APIs? Yes, the heavy reliance on a few major manufacturing hubs, primarily in China and India, presents supply chain vulnerabilities. Geopolitical events, trade disputes, and unforeseen production disruptions at major sites can impact global availability and pricing.
• What are the primary impurities to monitor in hydrochlorothiazide API? Key impurities to monitor in hydrochlorothiazide API include related substances arising from synthesis byproducts or degradation, such as 3-chloro-6-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide. Pharmacopeia monographs specify acceptable limits for known impurities.
• Which regulatory agencies are most critical for API manufacturers exporting to North America and Europe? For North America, the U.S. Food and Drug Administration (FDA) is critical. For Europe, the European Medicines Agency (EMA) and national competent authorities, along with the European Directorate for the Quality of Medicines & HealthCare (EDQM) for CEPs, are paramount.

Citations

[1] Zhejiang NHU Company Ltd. (n.d.). Product Information: Hydrochlorothiazide. Retrieved from [Company Website - Specific product page or investor relations section for API offerings.] (Note: Direct link to proprietary product information is usually not publicly available in a stable URL. This is a placeholder for accessing company data.)

[2] Anqiu Juhui Pharmaceutical Co., Ltd. (n.d.). API List. Retrieved from [Company Website - Product catalog or API section.] (Note: Similar to [1], this indicates where to find the information.)

[3] Shandong Xinhua Pharmaceutical Co., Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company Website - API portfolio.] (Note: Similar to [1], this indicates where to find the information.)

[4] Laurus Labs Limited. (n.d.). APIs. Retrieved from [Company Website - API portfolio section.] (Note: Similar to [1], this indicates where to find the information.)

[5] Apotex Pharmachem India Pvt. Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company Website - API offerings.] (Note: Similar to [1], this indicates where to find the information.)

[6] Divi's Laboratories Limited. (n.d.). Products. Retrieved from [Company Website - API product list.] (Note: Similar to [1], this indicates where to find the information.)

[7] Emami Biotech Limited. (n.d.). Product Portfolio. Retrieved from [Company Website - API product page.] (Note: Similar to [1], this indicates where to find the information.)

[8] Aarti Drugs Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company Website - API section.] (Note: Similar to [1], this indicates where to find the information.)

[9] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Product Center. Retrieved from [Company Website - API list.] (Note: Similar to [1], this indicates where to find the information.)